Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial

IMPORTANCE: The PCSK9 inhibitor evolocumab reduced major vascular events in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, yet the types and sizes of myocardial outcomes in FOURIER have not been previously explored. OBJECTIVE: To as...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Cardiol
Main Authors: Wiviott, Stephen D., Giugliano, Robert P., Morrow, David A., De Ferrari, Gaetano M., Lewis, Basil S., Huber, Kurt, Kuder, Julia F., Murphy, Sabina A., Forni, Danielle M., Kurtz, Christopher E., Honarpour, Narimon, Keech, Anthony C., Sever, Peter S., Pedersen, Terje R., Sabatine, Marc S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2020
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7191470/
https://ncbi.nlm.nih.gov/pubmed/32347885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2020.0764
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados